Muharrem Muftuoglu, M.D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | University of Istanbul, Cerrahpasa School of Medicine, Istanbul, TR, MD |
Postgraduate Training
| 2012-2018 | Postdoctoral Fellowship, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2012-2012 | Academic visitor, Experimental medicine, Imperial College, London |
| 2011-2012 | Clinical Fellowship, Hematology and Bone Marrow Transplant, University of Istanbul, Istanbul |
| 2006-2011 | Clinical Residency, Internal Medicine, University of Istanbul, Istanbul |
Licenses & Certifications
| 2011 | Turkish Board of Internal Medicine |
Experience & Service
Other Professional Positions
Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Clinical Fellow, University of Istanbul - Division of Hematology, Istanbul, 2011 - 2012
Resident, University of Istanbul, Istanbul, 2004 - 2011
Honors & Awards
| 2020 | Emerging Scientist Abstract Award, FlowTex |
| 2013 | Abstract Achievement Award, American Society of Hematology |
| 2006 | Valedictorian, University of Istanbul, Cerrahpasa School of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Multiplexed Single-Cell Proteomic Profiling in Acute Myeloid Leukemia. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. High Dimensional Analytic Approaches Identify Stressor Specific Response Patterns in AML. Conference. 13th Annual Flowtex Cytometry Conference. Houston, TX, US.
National Presentations
- 2023. Multiplexed CyTOF analysis of FLT3-ITD AML landscape identifies proteomic profiles associated with resistance to targeted therapies. Invited. AACR 2023. Austin, TX, US.
- 2022. Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax. Invited. 64th ASH Annual Meeting and Exposition. New Orleans, LA, US.
- 2020. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins. Conference. 62nd ASH Annual Meeting and Exposition, US.
- 2019. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns. Conference. 61st ASH Annual Meeting and Exposition, US.
- 2016. Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4: CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment "Fitness". Conference. 58th ASH Annual Meeting and Exposition, US.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | Localized Cytokine Delivery by Tumor-homing IL7-IL15-Fusokine-iMSC to Reverse Immune Exclusion in Platinum-resistant Ovarian Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00029473 |
| Date: | 2026 - Present |
| Title: | Combining Menin Inhibition with Next-Generation 5T4 CAR T Cells for AML Hierarchy-Spanning Targeting |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00029448 |
| Date: | 2026 - Present |
| Title: | Leveraging Menin Inhibitor-Induced Antigen-Presenting Cells to Enhance T Cell Immunity in Acute Myeloid Leukemia |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00029443 |
| Date: | 2026 - Present |
| Title: | Exploring the Impact of T Cell Intrinsic TP53 Mutations on Exhaustion and Immune Suppression in AML |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00028091 |
| Date: | 2026 - Present |
| Title: | TP53-Mutant T Cells in Immune Dysfunction and Microenvironmental Remodeling in AML |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00028221 |
| Date: | 2026 - Present |
| Title: | Harnessing Menin Inhibitor-Induced APCs to Elicit Anti-AML T Cell Immunity |
| Funding Source: | Rally Foundation for Childhood Cancer Research |
| Role: | Co-I |
| ID: | FP00029021 |
| Date: | 2026 - Present |
| Title: | Epichaperome Inhibition Restores T-Cell Function to Improve Immunotherapy in TP53-Mutant AML |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00027685 |
| Date: | 2026 - Present |
| Title: | Correlative Immune and Proteomic Analysis of PLM-102 in Relapsed/Refractory AML |
| Funding Source: | Pelemed |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Preclinical Assessment of Misetionamide Activity in High-Risk Acute Myeloid Leukemia |
| Funding Source: | Persevere Therapeutics |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Reprogramming the Leukemia Immune Interface via Menin Inhibition in KMT2A-r Leukemia |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | RA251153 |
| Date: | 2026 - Present |
| Title: | Menin Inhibition as a Novel Immunomodulatory Strategy in AML through Differentiation-Induced Reprogramming |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | RA250763 |
| Date: | 2026 - Present |
| Title: | Selective Targeting of AML Leukemic Stem Cells via 5T4-Directed Immunotherapy |
| Funding Source: | U.S. Department of Defense |
| Role: | PI |
| ID: | RA251117 |
| Date: | 2026 - Present |
| Title: | Assessment of ANT308-Mediated VIPR Blockade for Anti-AML Activity in Human In Vitro and In Vivo AML Models |
| Funding Source: | Cambium Oncology |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Leveraging Menin Inhibitor-Induced Antigen-Presenting Cells to Enhance T Cell Immunity in Pediatric Acute Myeloid Leukemia |
| Funding Source: | St Baldricks Foundation |
| Role: | Co-I |
| ID: | FP00029567 |
| Date: | 2026 - Present |
| Title: | Mechanistic Dissection and Mitochondrial Rescue of TP53-Mutant T-Cell Dysfunction in Acute Myeloid Leukemia |
| Funding Source: | Leukemia Research Foundation |
| Role: | Co-I |
| ID: | FP00030003 |
| Date: | 2026 - Present |
| Title: | Defining the Role of TP53-Mutant T Cells in Immune Suppression and Disease Evolution in Myelodysplastic Syndrome |
| Funding Source: | Edward P. Evans Foundation |
| Role: | Co-I |
| ID: | FP00029293 |
| Date: | 2026 - Present |
| Title: | Evaluating the Efficacy of the First-in-Class MASTL Inhibitor AD1208 Across Genetically and Clinically Diverse AML Subtypes |
| Funding Source: | Avelos Therapeutics |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Precision Targeting of AML Leukemic Stem Cells via 5T4-Directed CAR T Cells |
| Funding Source: | American Society for Transplantation and Cellular Therapy |
| Role: | Co-I |
| ID: | FP00027764 |
| Date: | 2026 - Present |
| Title: | Single-cell Proteomic Analysis of Lineage-Associated Siglec-7 and Siglec-9 Expression in Acute Myeloid Leukemia |
| Funding Source: | Immios Biotech |
| Role: | Co-PI |
| ID: | LS2026-00066390-HB |
| Date: | 2026 - Present |
| Title: | Harnessing Menin inhibitor-induced antigen presenting cells to potentiate T-cell therapy |
| Funding Source: | American Cancer Society |
| Role: | Co-I |
| ID: | FP00026711 |
| Date: | 2026 - Present |
| Title: | Harnessing Menin inhibitor-induced antigen-presenting cells to potentiate T cell immunity in acute myeloid leukemia |
| Funding Source: | American Society of Hematology |
| Role: | Co-I |
| ID: | FP00027436 |
| Date: | 2026 - Present |
| Title: | Integrative Gene-modified iMSC Strategy to Restore Anti-Tumor Immunity in Ovarian Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00026905 |
| Date: | 2026 - Present |
| Title: | Harnessing Menin Inhibition to Prime Acute Myeloid Leukemia for T-Cell Immunotherapy |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP00028885 |
| Date: | 2026 - Present |
| Title: | Reactivating TP53-Mutant T-Cells to Restore Anti-Leukemia Immunity in AML |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00026906 |
| Date: | 2025 - Present |
| Title: | Harnessing Menin inhibitor-induced antigen-presenting cells to potentiate T cell immunity in pediatric acute myeloid leukemia |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | FP00026906 |
| Date: | 2025 - Present |
| Title: | Targeting PLK1/TTK in AML – proposal for clinical trial monitoring |
| Funding Source: | SillaJen Biotherapeutics, Inc |
| Role: | Co-I |
| ID: | LS2025-00065634-LK |
| Date: | 2025 - Present |
| Title: | Armored Allogeneic CAR Gamma Delta T Cell Targeting CD70 for Acute Myeloid Leukemia with Relapsed/Refractory or Measurable Residual Disease |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00024214 |
| Date: | 2025 - Present |
| Title: | Targeting TP53 Mutant Immune Cells for Innovative AML Therapeutic Approaches |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00024185 |
| Date: | 2025 - Present |
| Title: | Reversing Mutant TP53-induced T-cell Dysfunction in AML to Boost Anti-tumor Immunity |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00023864 |
| Date: | 2025 - Present |
| Title: | IL-15-Armed, BCL2(G101V)-Engineered NK Cells Combined with Venetoclax for the Treatment of AML |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP00024925 |
| Date: | 2025 - 2030 |
| Title: | Therapeutic Vulnerabilities of TP53-Mutant Therapy-Related Myeloid Neoplasms (t-MNs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA292417-01A1 |
| Date: | 2025 - 2029 |
| Title: | Armored Allogeneic CD70 CAR-γδ T Cell for Acute Myeloid Leukemia with Relapsed/Refractory or Measurable Residual Disease |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Multi PI |
| ID: | RP250352 |
| Date: | 2025 - 2028 |
| Title: | Targeting nucleoside metabolism and anti-apoptotic mechanisms in high risk CMML |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | F00023138 |
| Date: | 2025 - Present |
| Title: | Targeting p53 Mutant Clonal Hematopoiesis and t-AML |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Co-I |
| ID: | FP00023924 |
| Date: | 2024 - Present |
| Title: | Targeting Mitochondrial Dynamics in Acute Myelogenous Leukemia Initiating Cells |
| Funding Source: | United States Department of Defense |
| Role: | Co-I |
| ID: | FP00020504 |
| Date: | 2024 - 2029 |
| Title: | MYC Protein Degradation Deconstructs Leukemia Cellular Hierarchy and Rewires Metabolism in TP53 Mutated Acute Myeloid Leukemias |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01-01 GRANT14060525 |
| Date: | 2024 - 2026 |
| Title: | Investigating the Role of IL7 and IL15-Secreting iMSCs in Inducing and Modulating Antitumor Immunity |
| Funding Source: | Eterna Therapeutics |
| Role: | Co-I |
| ID: | LS2024-00060984-AM1-HB |
| Date: | 2024 - Present |
| Title: | Targeting HSP90-epichaperome and mitochondrial HSP90 TRAP1 in therapy-resistant acute myeloid leukemia |
| Funding Source: | U.S. Department of Defense |
| Role: | Co-I |
| ID: | FP00020571 |
| Date: | 2024 - Present |
| Title: | IL-15 Armed and BCL2-Mutant Engineered NK-Cells for Targeting Relapsed/Refractory Pediatric Acute Myeloid Leukemia |
| Funding Source: | CURE Childhood Cancer |
| Role: | PI |
| ID: | FP00022321 |
| Date: | 2024 - Present |
| Title: | Therapeutic Vulnerabilities of TP53-Mutant AML from Pre-leukemic Stages to Full-blown Disease |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00020928 |
| Date: | 2024 - Present |
| Title: | HSP90-epichaperome and mitochondrial HSP90 TRAP1 inhibition in therapy-resistant AML |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00020916 |
| Date: | 2024 - 2029 |
| Title: | Development of Rational and Effective Strategies to Treat Patients with Myeloproliferative Neoplasm-Blast Phase |
| Funding Source: | NIH/NCI / Icahn School of Medicine at Mount Sinai |
| Role: | Co-I |
| ID: | FP00019689 |
| Date: | 2024 - Present |
| Title: | Tageting resistance in acute myeloid leukemia in the clinic: ERK 1/2inhibition in combination with hypomethylating agent |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | FP00019877 |
| Date: | 2024 - Present |
| Title: | Longitudinal Single‐cell Proteomic Analysis of AML Patients Treated with FLT3 or CD33‐gated CAR NK‐cells with Endomucin NOT Logic Gate |
| Funding Source: | Senti Bio |
| Role: | PI |
| ID: | RCTS13052026 |
| Date: | 2023 - 2026 |
| Title: | Multiplexed, Single‐cell Proteomic Assessment of Acute Myeloid Leukemia Proteomic Landscape in Patients Treated with CDK9 Inhibitor |
| Funding Source: | SELLAS Life Sciences Group, Inc |
| Role: | PI |
| ID: | RCTS #13052026 |
| Date: | 2023 - 2026 |
| Title: | Targeting Ferroptosis and Mitochondrial Pathways in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | CA220581 |
| Date: | 2023 - Present |
| Title: | Combining Armed NK-Cell Therapy with Targeted Therapies to Overcome Venetoclax Resistance in Acute Myeloid Leukemia |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| ID: | FP00019391 |
| Date: | 2023 - Present |
| Title: | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK cells for Acute Myeloid Leukemia |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00018453 |
| Date: | 2023 - Present |
| Title: | Therapeutic Induction of Ferroptosis in Therapy-Resistant AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| ID: | FP00015791_Res1 |
| Date: | 2023 - Present |
| Title: | Combining Epigenetic, Apoptosis Targeting, and Adoptive Cellular Therapy for Adverse Risk Acute Myeloid Leukemia |
| Funding Source: | DKMS |
| Role: | Co-I |
| ID: | FP00018240 |
| Date: | 2023 - Present |
| Title: | Ferroptosis-based Therapy in Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | PI |
| ID: | FP00016967 |
| Date: | 2023 - 2026 |
| Title: | Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) |
| Funding Source: | Break Through Cancer |
| Role: | Co-I |
| ID: | FP00018527 - Break Through Cancer AML MRD TeamLab |
| Date: | 2023 - 2024 |
| Title: | Integrated proteomics and transcriptomics approach to identify novel acute myeloid leukemia specific antigens and surface splice isoforms for immunotherapy |
| Funding Source: | Cancer Research Institute Technology Impact Award |
| Role: | Co-I |
| ID: | 65809 |
| Date: | 2022 - 2024 |
| Title: | Evaluating Logic-gated CAR-NK Cells in AML |
| Funding Source: | Senti Bio |
| Role: | PI |
| ID: | RCTS00060508 |
| Date: | 2022 - Present |
| Title: | Targeting Mitochondrial Respiration To Enhance Ferroptosis in Acute Myeloid Leukemia |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Co-I |
| ID: | FP00016486 |
| Date: | 2022 - Present |
| Title: | Mechanisms of Venetoclax Resistance in AML |
| Funding Source: | Leukemia & Lymphoma Society |
| Role: | Co-I |
| ID: | FP00016251 |
| Date: | 2022 - Present |
| Title: | Multimodal approach to identify novel antigens and splice variants for immunotherapy in AML |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| ID: | FP00016504 |
| Date: | 2022 - Present |
| Title: | Multiplexed Single-cell Proteomic detection and Interrogation of Measurable/Minimal Residual Cells in Acute Myeloid Leukemia |
| Funding Source: | When Everyone Survives Foundation |
| Role: | PI |
| ID: | FP00016848 |
| Date: | 2022 - Present |
| Title: | Therapeutic targeting of p53 reactivation-induced metabolic reprogramming and stress responses to overcome resistance to venetoclax/HMA in AML |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Co-I |
| ID: | FP00016508 |
| Date: | 2022 - 2027 |
| Title: | Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| Date: | 2022 - 2025 |
| Title: | Integrated immuno-genomic/proteomic profiling and prediction for AML |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230263 |
| Date: | 2022 - 2024 |
| Title: | Assessment of Leukemia Proteomic Landscape to Optimize Immunotherapeutic Approaches in Acute Myeloid Leukemia |
| Funding Source: | AstraZeneca (United States) |
| Role: | Co-I |
| ID: | LS2022-00061143-LK |
| Date: | 2022 - 2024 |
| Title: | IPS-derived MSC (iMSC) Homing to Bone Marrow and Evaluation for Support of Hematopoiesis |
| Funding Source: | Brooklyn ImmunoTherapeutics |
| Role: | Co-I |
| ID: | LS2022-00060984-HB |
| Date: | 2022 - 2025 |
| Title: | Mitochondria-mediated Enhancement of Ferroptosis Induction in Therapy Resistant AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| Date: | 2022 - 2023 |
| Title: | Integrating Next Generation Clustered Heat Map (NGCHM) with Texomer Web Portal |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01 CA 24776 |
| Date: | 2022 - 2023 |
| Title: | Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to Venetoclax/HMA in AML |
| Funding Source: | NIH/NCI |
| Role: | Research Scientist |
| ID: | 1 R21 CA267401-01 |
Selected Publications
Peer-Reviewed Articles
- Li L, Muftuoglu M, Ayoub E, Lv J, Basyal M, Zhao R, Menon PS, Bidikian A, Mak PY, Nishida Y, Kesharwani RK, Issa GC, Varadarajan N, Carter B, Andreeff M. Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53. e-Pub 2026.
- Zhang, W, Li, L, Muftuoglu, M, Basyal, M, Togashi, N, Iwanaga, K, Tanzawa, F, Numata, M, Bixby, D, Erba, HP, Podoltsev, N, Schiller, GJ, Kumar, P, Lesegretain, A, Isoyama, T, Seki, T, Daver, N, Andreeff, M. Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. Clinical Cancer Research 31(14):3033-3047, 2025. e-Pub 2025. PMID: 40327322.
- Veletic, I, Harris, D, Rozovski, U, Bertilaccio, MS, Calin, GA, Takahashi, K, Li, P, Liu, Z, Manshouri, T, Drula, R, Furudate, K, Muftuoglu, M, Hossain, A, Wierda, WG, Keating, M, Estrov, Z. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia 39(6):1380-1394, 2025. e-Pub 2025. PMID: 40186065.
- Pourebrahim R, Montoya RH, Akiyama H, Ostermann L, Khazaei S, Muftuoglu M, Baran N, Zhao R, Lesluyes T, Liu B, Khoury JD, Gagea M, Van Loo P, Andreeff M. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med 5(5):101558, 2024. e-Pub 2024. PMID: 38733986.
- Chang KH, Zhang W, Muftuoglu M, Basyal M, Ostermann L, Mak PY, Jia Y, Tao W, Fogler WE, Magnani JL, Carter BZ, Andreeff M. E-Selectin Inhibition Overcomes Endothelial Niche-Mediated Resistance to Bcl-2–Targeted Therapy in AML. e-Pub 2024.
- Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
- Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
- Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, Jiang L, Wu D, Hu Y, Zhang H, Xu P, Cheng S, Wang L, Lacin S, Muftuoglu M, Zhao W. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Front Med 17(4):699-713, 2023. e-Pub 2023. PMID: 37060525.
- Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):80, 2023. e-Pub 2023. PMID: 37193700.
- Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
- Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35230977.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M. Transgenic Expression of IL15 retains CD123-redirected T-cells in a less differentiated state resulting in improved anti-AML activity in autologous AML PDX models. Front Immunol 13:880108, 2022. e-Pub 2022. PMID: 35615350.
- Miao Q, Wang F, Dou J, Iqbal R, Muftuoglu M, Basar R, Li L, Rezvani K, Chen K. Ab initio spillover compensation in mass cytometry data. Cytometry A 99(9):899-909, 2021. e-Pub 2021. PMID: 33342071.
- Muftuoglu M, Li L, Liang S, Mak D, Lin AJ, Fang J, Burks JK, Chen K, Andreeff M. Extended live-cell barcoding approach for multiplexed mass cytometry. Sci Rep 11(1):12388, 2021. e-Pub 2021. PMID: 34117319.
- Liang S, Mohanty V, Dou J, Miao Q, Huang Y, Muftuoglu M, Ding L, Peng W, Chen K. Publisher Correction: Single-cell manifold-preserving feature selection for detecting rare cell populations. Nat Comput Sci 1(6):448, 2021. e-Pub 2021. PMID: 38217241.
- Liang S, Mohanty V, Dou J, Miao Q, Huang Y, Muftuoglu M, Ding L, Peng W, Chen K. Single-cell manifold-preserving feature selection for detecting rare cell populations. Nat Comput Sci 1(5):374-384, 2021. e-Pub 2021. PMID: 36969355.
- Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang MC, Zheng Z, Li J, Zhao WL. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. Clin Cancer Res 25(23):6995-7003, 2019. e-Pub 2019. PMID: 31444250.
- Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. e-Pub 2018. PMID: 30304652.
- Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
- Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32(4):960-970, 2018. e-Pub 2018. PMID: 28972595.
- Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520-531, 2018. e-Pub 2018. PMID: 28725044.
- Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
- Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129(6):740-758, 2017. e-Pub 2017. PMID: 27821506.
- Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K. Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol 8:1937, 2017. e-Pub 2017. PMID: 29375566.
- Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2017. PMID: 29379494.
- Alsuliman A, Appel SH, Beers DR, Basar R, Shaim H, Kaur I, Zulovich J, Yvon E, Muftuoglu M, Imahashi N, Kondo K, Liu E, Shpall EJ, Rezvani K. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy 18(10):1312-24, 2016. e-Pub 2016. PMID: 27497700.
- Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
- Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
- Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 124(13):2034-45, 2014. e-Pub 2014. PMID: 25051962.
- Gurler N, Oksuz L, Muftuoglu M, Sargin F, Besisik S. Bacillus cereus catheter related bloodstream infection in a patient with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 4(1):e2012004, 2012. e-Pub 2012. PMID: 22348186.
- Kayacan SM, İşak B, Kayacan D, Müftüoğlu M, Karadag A. THE IMPORTANCE OF CUTANEOUS SILENT PERIOD IN UREMIC POLYNEUROPATHY, 2011. e-Pub 2011.
Review Articles
- Muftuoglu M, Andreeff M. Sample multiplexing in CyTOF: Path to optimize single-cell proteomic profiling. Cell Signal (Middlet), 2024. e-Pub 2024. PMID: 40182016.
Abstracts
- Andreeff M, Singh S, Bedoy A, Muftuoglu M, Li L, Anand V, Nath D, Ostermann L, Vletic I, Pacheco CD, Basyal M, Kim T, Garland KM, Angel M, Luther S, Pierce R, Rohde CB. Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells convert the immunosuppressive into immune-activated tumor microenvironments (TME) and potentiate antitumor immunity. Cancer Res, 2026. e-Pub 2026.
- Yilmaz M, Muftuoglu M, Short N, Loghavi S, Kadia T, Dinardo C, Borthakur G, Pemmaraju N, Alvarado Y, Maiti A, Konopleva M, Masarova L, Montalban G, Jurisprudencia C, Pike A, Patel K, Tang G, Matthews J, Kornblau S, Jabbour E, Garcia-Manero G, Takahashi K, Ravandi F, Andreeff M, Kantarjian H, Daver N. Triplet Therapy With Decitabine, Venetoclax, and Quizartinib for FLT3-ITD Mutated AML: A Phase 1/2 Study. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025.
- Singh S, Bedoy AD, Muftuoglu M, Nath D, Li L, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a" cold" ovarian tumor model. Blood, 2025. e-Pub 2025.
- Strickland SA, Eghtedar A, Farhadfar N, Bajel AR, Ravandi F, Emery R, Garrison B, Muftuoglu M, Andreeff M, Rajangam K, Schiller G. First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data. Cancer Res, 2025. e-Pub 2025.
- Muftuoglu M, Hong E, Strickland SA, Eghtedar A, Schiller G, Farhadfar N, Bajel AR, Ravandi F, Basyal M, Li L, Naitmazi L, Emery R, Garrison BS, Lu T, Rajangam K, Andreeff M. Abstract CT143: First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic Malignancies including AML: Correlative data. Cancer Res, 2025. e-Pub 2025.
- Muftuoglu M, Li L, Basyal M, Lv J, Ostermann LB, Deng H, Wong P, Lu T, Garrison B, Rajangam K, Andreeff M. SENTI-202 CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML while protecting human HSC/HPCs from off-tumor toxicity in a humanized mouse model. Cancer Res, 2025. e-Pub 2025.
- Maiti A, Ramdial J, DiNardo C, Chien K, Muftuoglu M, Duose D, Haymaker C, Jain N, Hammond D, Issa G, Ohanian M, Sasaki K, Lim M, Li J, Ignatz-Hoover J, Xiao L, Huang X, Patel K, Reese J, Litten J, Astrow S, Andreeff M, Ravandi F, Tomlinson B, Daver N, Wald D. Phase 1 Trial of Azacitidine, Venetoclax, and Allogeneic NK Cells in Acute Myeloid Leukemia (ADVENT-AML): Results From Dose-Escalation Phase. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025.
- Singh S, Bedoy A, Nath D, Chang KH, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Muftuoglu M, Basyal M, Kim T, Hinkel RD, Garland KM, Angel M, Luther S, Rohde CB, Andreeff M. iPS-derived MSC secreting IL7 and IL15 exert immune mediated anti-tumor activities. Cancer Res, 2025. e-Pub 2025.
- Khanna P, Yang D, Muftuoglu M, Ostermann L, Khazaei S, Zhao R, Basyal M, Andreeff M, Gagea M, Li R, Takahashi K, Pourebrahim R. Immune mediated expansion of p53 mutant clonal hematopoiesis following carboplatin treatment. Cancer Res, 2025. e-Pub 2025.
- Basyal M, Muftuoglu M, Li L, Lv J, Tan Y, Chen K, Andreeff M. “Baseline-informed” unsupervised multiplexed CyTOF analysis enhances detection of minimal/measurable residual disease in acute myeloid leukemia. Cancer Res, 2025. e-Pub 2025.
- Muftuoglu M, Singh S, Bedoy AD, Li L, Nath D, Ostermann LB, Veletic I, Pacheco CD, Mak PY, Ayoub E, Basyal M, Kim T, Luther S, Rohde CB, Andreeff M. Gene-modified iPS-derived MSC restore a ‘Hot’immune microenvironment in high-grade serous ovarian cancer. Cancer Res, 2025. e-Pub 2025.
- Muftuoglu M, Singh S, Bedoy A, Li L, Basyal M, Dipmoy N, Ostermann L, Veletic I, Pacheco C, Mak PY, Ayoub E, Kim T, Garland K, Pierce R, Angel M, Luther S, Rohde C, Andreeff M. Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes. Blood, 2025. e-Pub 2025.
- Li L, Muftuoglu M, Basyal M, Bedoy A, Issa G, Daver N, Andreeff M. Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX). Blood, 2025. e-Pub 2025.
- Singh S, Bedoy A, Muftuoglu M, Li L, Okeleji O, Dipmoy N, Ostermann L, Veletic I, Pacheco C, Basyal M, Kim T, Garland KM, Angel M, Luther S, Rohde C, Anand V, Andreeff M. Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity. Blood, 2025. e-Pub 2025.
- Li L, Muftuoglu M, Ayoub E, Bidikian A, Menon P, Basyal M, Bedoy A, Tyagi A, Eckstrom A, Battula VL, Issa G, Varadarajan N, Carter B, Andreeff M. Reactivating mutant p53 in T cells enhances anti-tumor activity in Acute Myeloid Leukemia. Blood, 2025. e-Pub 2025.
- Muftuoglu M, Hong E, Farhadfar N, Strickland S, Bajel A, Eghtedar A, Schiller G, Basyal M, Li L, Naitmazi L, Emery R, Lu T, Garrison B, Rajangam K, Ravandi F, Andreeff M. Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action. Blood, 2025. e-Pub 2025.
- Pourebrahim R, Khanna P, Yang D, Muftuoglu M, Ostermann LB, Khazaei S, Zhao R, Asare A, Hajek RA, Lee S, Corvingo S, Gagea M, Sood A, Li R, Takahashi K, Andreeff M. Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors. Blood, 2024. e-Pub 2024.
- Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Pemmaraju N, Valero YA, Maiti A, Konopleva M, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Takahashi K, Andreeff M, Ravandi F, Kantarjian HM, Daver N. Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood, 2024. e-Pub 2024.
- Li L, Muftuoglu M, Ayoub E, Bidikian A, Menon P, Lv J, Basyal M, Bedoy A, Tyagi A, Eckstrom A, Battula VL, Varadarajan N, Issa GC, Andreeff M. TP53 mutations within T cells induce T-cell exhaustion and functional impairment in TP53 mutant AML. Blood, 2024. e-Pub 2024.
- Pourebrahim R, Yang D, Khanna P, Muftuoglu M, Ostermann LB, Khazaei S, Zhao R, Gagea M, Colla S, Garcia-Manero G, Li R, Andreeff M, Takahashi K. Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms. Blood, 2024. e-Pub 2024.
- Ayoub E, Lehotzky D, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, Haferlach T, Takahashi K, Chen K, Navin N, Issa GC, Getz G, Andreeff M. Single-cell multiomics unveils venetoclax-resistant monocytic differentiation and immune evasion in TP53 mutant AML clones. Blood, 2024. e-Pub 2024.
- Muftuoglu M, Basyal M, Li L, Lv J, Ostermann L, Zhao R, Ke B, Akiyama H, Mak PY, Carter BZ, Deng H, Li Y, Garrison B, Rajangam K, Andreeff M. Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-02) in Venetoclax Resistant Patient Derived Xenograft aml Models. 65th ASH Annual Meeting and Exposition, 2023. e-Pub 2023.
- Muftuoglu M, LiLi, Basyal M, Ayoub E, Lv J, Bedoy A, Patsilevas T, Bidikian A, Issa G, Andreeff M. Single-Cell Proteomic Analysis Reveals Menin Inhibition-Induced Proteomic Alterations in AML Patients Treated with Revumenib. 65th ASH Annual Meeting and Exposition, 2023. e-Pub 2023.
- Sharma P, Ostermann LB, Piya S, Ke B, Baran N, Tyagi A, Muftuoglu M, Basyal M, Zhang Q, Munck J, Dao K, Sims M, Carter BZ, Battula VL, Andreeff M, Borthakur G. ERK1/2 Inhibition overcomes resistance to venetoclax in AML by inhibiting Drp1 dependent mitochondrial fission. Blood, 2023. e-Pub 2023.
- Veletic I, Harris DM, Rozovski U, Li P, Liu Z, Manshouri T, S Bertilaccio MT, Calin GA, Drula R, Takahashi K, Furudate K, Muftuoglu M, Hossain A, Ferrajoli A, Burger JA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL. Blood, 2023. e-Pub 2023.
- Wang X, Davis A, Su X, Muftuoglu M, Krejsa C, Mascarenhas J, Andreeff M, Hoffman R. TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME). Blood, 2023. e-Pub 2023.
- Maiti A, Muftuoglu M, Ignatz-Hoover JJ, DiNardo CD, Ravandi F, Andreeff M, Xiao L, Huang X, Patel KP, Litten JB, Bourk E, Astrow S, Kantarjian HM, Tomlinson BK, Daver N, Wald D. Azacitidine, venetoclax and allogeneic NK cells in newly diagnosed acute myeloid leukemia (ADVENT-AML): an investigator-initiated multicenter phase Ib trial. Blood, 2023. e-Pub 2023.
- Li L, Muftuoglu M, Basyal M, Daver N, Andreeff M. Abstract A07: Single-cell proteomic assessment of FLT3-ITD AML landscape identifies distinct resistance patterns. Blood Cancer Discov, 2023. e-Pub 2023.
- Muftuoglu M, Li L, Basyal M, Lv J, Tan Y, Chen K, Andreeff M. “Guided” Unsupervised Multiplexed Cytof Analysis Enhances Detection of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia. Blood, 2023. e-Pub 2023.
- Ayoub E, Mohanty V, Nishida Y, Patsilevas T, Basyal M, Pourebrahim R, Muftuoglu M, Chen K, Issa GC, Andreeff M. Abstract A41: Single Cell Multiomic Analysis Reveals Association of TP53-mut Loss of Heterozygosity with Primitive Phenotype in Acute Myeloid Leukemia. Blood Cancer Discov, 2023. e-Pub 2023.
- Ayoub E, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, Haferlach T, Takahashi K, Chen K, Navin N, Issa GC, Andreeff M. Single-cell genomics and proteomics reveals Venetoclax-resistant monocytic differentiation of TP53 LOH clones in TP53 mutant AML. Blood, 2023. e-Pub 2023.
- Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver N. Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood, 2023. e-Pub 2023.
- Muftuoglu M. Multiplexed CyTOF analysis of FLT3-ITD AML landscape identifies proteomic profiles associated with resistance to targeted therapies. AACR 2023, 2023. e-Pub 2023.
- Muftuoglu M. Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax. 64th ASH Annual Meeting and Exposition, 2022. e-Pub 2022.
- Ong F, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Ohanian M, Konopleva M, Jabbour E, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Sasaki K, Chien KS, Takahashi K, Andreeff M, Muftuoglu M, Delumpa R, Mayor E, Loiselle C, Waller L, Banks G, Kantarjian H, Cortes JE, Short N. A phase I/II study of combination of azacitidine, venetoclax and pevonedistat in patients with newly-diagnosed secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with hypomethylating agent (HMA) failure. Blood, 2022. e-Pub 2022.
- Sharma P, Piya S, Baran N, Muftuoglu M, Basyal M, Ruvolo V, Hindley CJ, Dao K, Sims M, Andreeff M, Borthakur G. Inhibition of ERK1/2 reverses venetoclax-induced autophagy to overcome resistance in acute myeloid leukemia. Blood, 2022. e-Pub 2022.
- Senapati J, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Issa GC, Dara SI, Pourebrahim R, Daver N, Jabbour EJ, Kornblau SM, Pemmaraju N, Garcia-Manero G, Ravandi F, Muftuoglu M, Khoury J, DiNardo C, Andreeff M. P576: a Phase I/Ii study of milademetan (Ds3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. Hemasphere, 2022. e-Pub 2022.
- Sharma P, Piya S, Ma H, Baran N, Muftuoglu M, Basyal M, Ruvolo V, Ward G, Smyth T, Sims MJ, Andreeff M, Borthakur G. Tolinapant (ASTX660) enhances the anti-leukemic activity of Venetoclax and Dexamethasone in T cell acute lymphoblastic leukemia (T-ALL). Cancer Res, 2022. e-Pub 2022.
- Yilmaz M, Muftuoglu M, Kantarjian HM, Dinardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Bravo GM, Loghavi S, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, Daver NG. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. J Clin Oncol. e-Pub 2022.
- Yilmaz M, Kantarjian HM, Muftuoglu M, Kadia TM, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short NJ, Alvarado Y, Moltalban Brava G, Jurisprudencia C, Pike AM, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML). Journal of Clinical Oncology 39 (15 supplement):e19019. e-Pub 2021.
- Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann L, Montoya RH, Muftuoglu M, Ruvolo V, Mak PY, Tao W, Carter BZ, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation by Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. Blood, 2021. e-Pub 2021.
- Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, Cortes JE. Azacitidine, venetoclax and pevonedistat as frontline therapy for patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy: results from a phase I/II study. Blood, 2021. e-Pub 2021.
- Muftuoglu M, Li L, Basyal M, Liang S, Ball CJ, Chen K, Kumar P, Lesegretain A, Daver N, Andreeff M. Single-cell proteomics identifies leukemia landscape associated with clinical outcomes in R/R AML treated with MDM2i (milademetan) and FLT3i (quizartinib): putative role of CD68 and diversity index. Blood, 2021. e-Pub 2021.
- Chang KH, Zal T, Basyal M, Ostermann L, Muftuoglu M, Mak PY, Jia Y, Tao W, Zal MA, Fogler WE, Magnani JL, Zhang W, Carter BZ, Andreeff M. Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy. Blood, 2021. e-Pub 2021.
- Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML)-RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood, 2021. e-Pub 2021.
- Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo P, Carter BZ, Andreeff M. AML-356: High Dimensional Analytic Approaches Identify Stressor Specific Response Patterns in AML. Clin Lymphoma Myeloma Leuk, 2020. e-Pub 2020.
- Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo P, Carter BZ, Andreeff M. High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
- Muftuoglu M, Alaniz Z, Mak D, Lin A, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
- Chang KH, Muftuoglu M, Zhang W, Basyal M, Ostermann LB, Fogler WE, Magnani JL, Andreeff M. Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
- Yilmaz M, Kantarjian HM, Muftuoglu M, Kadia TM, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short NJ, Alvarado Y, Moltalban Brava G, Jurisprudencia C, Pike AM, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. 62nd ASH Annual Meeting and Exposition, 2020. e-Pub 2020.
- Muftuoglu M, Alaniz Z, Mak D, Lin A, Burks J, Carter BZ, Andreeff M. AML-354: High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Patients with Relapsed/Refractory AML. Clin Lymphoma Myeloma Leuk, 2020. e-Pub 2020.
- Muftuoglu M, Li L, Mak D, Shaim H, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Bdiwi, MH, Jimenez J, Banarjee PP, Lim F, Kerbauy L, Kaplan M, DePombo A, Mendt MC, Basar R, Daher M, Marin D, Wang J, Andreeff M, Wierda WG, Jain N, Thompson P, Keating MJ, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Evaluation of T Cell Compartment By Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Shaim H, Alsuliman A, Gabrusiewicz K, Wei J, Yu J, Basar R, Daher M, Kerbauy L, Mendt M, DePombo A, Huertas-Herrera A, Mendt MC, FLWI L, Gi Y, Tong Y, Kaur I, Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Imahashi N, Kerbauy LN, Li L, Liu E, Lu J, Ang S, Bdiwi MH, Jimenez J, Banerjee PP, Champlin RE, Kurtzberg J, Rezvani K, Large-Scale SE, Annual Meeting BEOUCBTMSCFCUA, Exposition, Atlanta, USA, Li L, Liu E, Imahashi N, Ang S, y G, Banarjee PP, Marin D, Champlin RE, Shpall EJ, Heimberger A, Rezvani K. TGF-β is a key mediator of NK cell dysfunction in gliolastoma. AACR, 2017. e-Pub 2017.
- Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Kontoyiannis A, Mendt MC, Imahashi N, Kerbauy LN, Wei Inng Lim FL, Li L, Muftuoglu M, Banerjee PP, Champlin RE, Ruvolo PP, Andreeff M, Kantarjian HM, Garcia-Manero G, Shpall ES, Rezvani R. The TGF-b/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Kerbauy LN, Ang S, Liu E, Banerjee PP, Wu Y, Shaim H, Lim FL, Basar R, Li L, Muftuoglu M, Daher M, Imahashi N, Mendt MC, Kaplan M, Mukherjee M, Lee JCH, Orange J, Konopleva M, Andreeff M, Champlin RE, Shpall ES, Rezvani R. Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- DePombo A, Huertas-Herrera A, Mendt MC, FLWI L, Gi Y, Tong Y, Kaur I, Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Imahashi N, Kerbauy LN, Li L, Liu E, Lu J, Ang S, Bdiwi MH, Jimenez J, Banerjee PP, Champlin RE, Kurtzberg J, Rezvani K, Shpall EJ. Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Li L, Muftuoglu M, Chen H, Mak D, Burks JK, Mehta R, Xi Y, Lv J, Hu B, Jimenez J, Kaplan M, Shaim H, Imahashi N, Banerjee PP, Kerbauy L, Mendt M, Lim, F, Daher M, DePombo A, Basar R, Andreeff M, Wang J, Marin D, Champlin R, Shpall EJ, Rezvani K. NK Cell Diversity Influences Outcomes after Cord Blood Transplantation. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, Kerbauy L, Lu J, Lim F, Mendt M, DePombo A, Daher M, Basar R, Neelapu S, Orlowski RZ, Andreeff M, Marin D, Champlin R, Shpall EJ, Rezvani K. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Muftuoglu M, Li L, Jimenez J, Mak D, Shaim H, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Lim F, Banarjee PP, Bdiwi MH, Kerbauy L, Kaplan M, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Exploring the Cord Blood T Cell Compartment with Mass Cytometry Reveals the Existence of Memory CD4, CD8 and Regulatory T Cell Pools in the Fetal Period. 59th ASH Annual Meeting and Exposition, 2017. e-Pub 2017.
- Olson AL, Muftuoglu M, Kaur I, Li L, Abueg G, Chemaly R, Yvon E, Thall PF, Marin D, Alousi AM, Ahmed S, Hosing C, Ciurea SO, Kebriaei P, Jones R, Andersson BS, Shah N, Oran B, Abudayyeh A, Popat U, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Muftuoglu M, Ahmed S, Olson A, Mulanovich V, Li L, Verstovsek S, Kaur I, Abueg G, Marin D, Yvon E, Champlin RE, Shpall EJ, Rezvani K. Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy. 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Muftuoglu M, Li L, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Basar R, Imahashi N, Mendt MC, Daher M, Marin D, Wierda WG, Jain N, Keating MJ, Champlin RE, Shpall EJ, Rezvani K. Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4: CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment" Fitness". 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Li L, Muftuoglu M, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Daher M, Imahashi N, Vilchez MC, Basar R, Marin D, Champlin RE, Shpall EJ, Rezvani K. Cytomegalovirus Reactivation Shapes NK Cells Diversity Following Allogeneic Hematopoietic Stem Cell Transplantation. 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Daher M, Marin D, Sobieski C, Shaim H, Basar R, Vilchez MC, Gokdemir E, Li L, Imahashi N, Muftuoglu M, Champlin RE, Shpall EJ, Rezvani K. KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Shah N, Hosing C, Olson AL, Parmar S, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. 58th ASH Annual Meeting and Exposition, 2016. e-Pub 2016.
- Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper LJN, Lee DA, Parmar, S, Cao K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. 57th ASH Annual Meeting and Exposition, 2015. e-Pub 2015.
- Liu E, Tong Y, Dotti G, Savoldo B, Muftuoglu M, Kondo K, Mukherjee M, Orange JS, Sobieski C, Alsuliman A, Shaim H, Imahasi N, Keating MJ, Hosing CM, Shah N, Wierda W, Champlin RE, Shpall EJ, Rezvani K. Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity. 57th ASH Annual Meeting and Exposition, 2015. e-Pub 2015.
- Shaim H, Estrov Z, Sekine T, Kondo K, Ruvolo P, Thompson P, Sarvaria A, Muftuoglu M, Imahashi N, Liu E, Sobieski C, Wierda W, Keating MJ, Shah N, Hosing CM, Alsuliman A, Basar B, Ferrajoli A, Shpall E, Rezvani K. The CXCR4/STAT3/IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia (CLL) and Can be Modulated By Lenalidomide. 57th ASH Annual Meeting and Exposition, 2015. e-Pub 2015.
- Shaim H, Alsuliman A, Gabrusiewicz KR, Wei J, Yu J, Basar R, Kondo K, Muftuoglu M, Liu E, Imahashi N, Sobieski C, Tong Y, Yvon E, Champlin R, Shpall E, Heimberger A, Rezvani K. Glioblastoma infiltrating NK cells are dysfunctional and have a severely altered phenotype. NK2015 15th Meeting of the Society for Natural Immunity, 2015. e-Pub 2015.
- Kondo K, Burger JA, Keating MJ, Tran J, Muftuoglu M, Daher M, Shaim H, Thompson P, Imahashi N, Alsuliman A, Wierda W, Liu E, Shpall EJ, Rezvani K. Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions brutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. 57th ASH Annual Meeting and Exposition, 2015. e-Pub 2015.
- Muftuoglu M, Alsuliman A, Khoder A, Ahn YO, Liu E, Chew C, Hamdi A, Sekine T, Sarvaria A, Cooper N, De Lavallade H, Marin D, Stringaris K, Verneris MR, Shpall EJ, and Rezvani K. CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy. 55th ASH Annual Meeting and Exposition, 2013. e-Pub 2013.
- Sarvaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, De Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, St John LS, Marin D, Stringaris K, Liu E, Molldrem JJ, Shah N, Parmar S, McNiece IK, Champlin RE, Shpall EJ, Rezvani K. B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease. 55th ASH Annual Meeting and Exposition, 2013. e-Pub 2013.
- Muftuoglu M, Osmanbasoglu E, Kalayoglu-Besisik S, Sargin F. GUILLAIN-BARRE SYNDROME AFTER STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE. Haematologica, 2012.
- Muftuoglu M, Gurses N, Sargin F, Kalayoglu-Besisik S. Secondary cancers following stem cell transplantation: A single center experience. Haematologica, 2012. e-Pub 2012.
- Muftuoglu M, Gurses-Koc N, Savran-Oguz F, Sargin D, Kalayoglu-Besisik S. Effect of HLA allels on graft-versus-host disease occurrence in Turkish patients receiving a human leukocyte antigen-identical haematopoietic stem cell transplant: P563. Bone Marrow Transplant 47, 2012.
- Kayacan SM, Vatansever S, Müftüoğlu M, Karadağ A, Büyükbabani N, Akkaya V, Erk O, Güler K. A CASE OF NEPHROGENIC FIBROSING DERMOPATHY IN A HEMODIALYSIS PATIENT. Eur J Intern Med 20, 2009. e-Pub 2009.
- Kerbauy L, Kaplan M, Banerjee PP, FLWI L, Nunes-Cortes AK, Daher D, Mendt MC, Basar R, Li L, Muftuoglu M, Shaim H, Shanley M, Liu E, Ang S, Cai R, Nandivada V, Champlin RE, Koch J, Treder M, Shpall EJ, Rezvani K. Cord Blood Derived Natural Killer Cells Loaded with a Tetravalent Bispecific Antibody Construct (AFM13) As Off-the-Shelf Cell Therapy for CD30+ Malignancies. Blood 132 (Supplement 1):341.
- Mu-Mosley H, Ostermann LB, Muftuoglu M, Schober W, Patel NB, Vaidya A, Bonifant CL, Gottschalk S, Velasquez MP, Andreeff M. Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity. Blood, The Journal of the American Society of Hematology 134 (Supplement 1):3917.
- Muftuoglu M, Ruvolo V, Nishida Y, Mak PY, Ruvolo P, Carter BZ, Andreeff M. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns. Blood, The Journal of the American Society of Hematology 134 (Supplement 1):882.
- Aung FM, Lichtiger B, Kaur I, Muftuoglu M, Shpall E, Rezvani K. Peripheral Blood Mononuclear Cells from Buffy Coats Processed from Healthy Whole Blood Donors for the Production of Third Party Viral Specific Cytotoxic T Lymphocytes. In Transfusıon 57:112A.
- Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo P, Carter BZ, Andreeff M. High Dimensional Analytic Approaches Identify Stressor Specific Response Patterns in AML. Clinical Lymphoma Myeloma and Leukemia 20:S207.
- Muftuoglu M, Alaniz Z, Mak D, Lin A, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Patients with Relapsed/Refractory AML. Clinical Lymphoma Myeloma and Leukemia 20:S206-S207.
Letters to the Editor
- Akiyama, H, Nishida, Y, Chang, KH, Bedoy, AD, Muftuoglu, M, Ma, W, Basyal, M, Hirschi, Z, Honma, D, Tsutsumi, S, Wang, J, Zhang, W, Huang, X, Rampal, R, Oluwole, OO, Bixby, D, Daver, N, Andreeff, M. Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. Blood cancer journal 15, 2025.
Patents
- Andreeff M, Muftuoglu M. Extended live cell barcoding approach for multiplexed mass cytometry. Patent Number: US20250198996A1.
- Katy REZVANI, Elizabeth SHPALL, Muharrem MUFTUOGLU. BK Virus Specific T Cells. Patent Number: US Patent 10,821,134.
Patient Reviews
CV information above last modified July 22, 2026